FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959649660> ?p ?o ?g. }

• W2959649660 abstract "7521 Background: MOR208, an Fc-enhanced, humanized, anti-CD19 monoclonal antibody has shown single agent activity in patients (pts) with R-R DLBCL and encouraging activity when combined with LEN in the phase II L-MIND study. Here we report an update with primary endpoint and subgroup analyses (cut off June 5, 2018). Methods: Key inclusion criteria were adequate organ function, ≤3 prior lines of therapy, including ≥1 anti-CD20 therapy, and ineligibility for stem cell transplantation. Treatment comprised up to 12, 28-day (d) cycles (C) of MOR208, 12 mg/kg IV, q1w C1–3 (loading dose on d4 of C1), and q2w C4–12 + LEN 25 mg PO d1–21, C1–12. Pts progression-free after 12 C received MOR208 q2w until progression. The primary endpoint was independent review committee (IRC)-assessed ORR as per Cheson 2007 criteria. Results: Recruitment is complete (N = 81): median age 72 years (range 41–87), median of 2 prior therapies, 19 (23%) of pts had early relapse (≤12 months [mo] from diagnosis), 32 (40%) were rituximab (RTX) refractory (no response to or progression during or within 6 mo of a prior RTX therapy), 34 (42%) were refractory to their last therapy, 21/40 (26%/49%) pts had non-germinal center B cell-like (GCB)- / GCB-DLBCL, and 42 (52%) had an International Prognostic Index (IPI) of 3–5. MOR208 + LEN therapy was well tolerated; 72% of pts stayed on a LEN dose of ≥20 mg/day. Treatment-related serious adverse events, mainly infections (10%) or neutropenic fever (5%), occurred in 17% of pts. Investigator (INV)-assessed complete response (CR) and partial response rates were 33% and 25%, respectively, giving an ORR of 58%, comparable to the IRC assessment (ORR 54%; CR 32%). ORR was 46% in pts with ≥2 prior therapies, 59%/56% in rituximab- / last treatment-refractory pts, 58% in early relapse pts, 57% in pts with a baseline IPI of 3–5, and 71% in pts with non-GCB- vs 53% with GCB-DLBCL. INV-assessed median PFS and OS (ITT analysis) were 16.2 mo (95% CI: 6.3–NR) and not reached (95% CI: 18.6–NR), respectively. Conclusions: MOR208 + LEN shows encouraging activity including a durable PFS in R-R DLBCL, and in pt subgroups with poor prognosis. Clinical trial information: NCT02399085." @default.
• W2959649660 created "2019-07-23" @default.
• W2959649660 creator A5007316044 @default.
• W2959649660 creator A5007901103 @default.
• W2959649660 creator A5013293066 @default.
• W2959649660 creator A5014125875 @default.
• W2959649660 creator A5016764336 @default.
• W2959649660 creator A5024389256 @default.
• W2959649660 creator A5035549893 @default.
• W2959649660 creator A5041745367 @default.
• W2959649660 creator A5046049357 @default.
• W2959649660 creator A5050782079 @default.
• W2959649660 creator A5061317839 @default.
• W2959649660 creator A5063710613 @default.
• W2959649660 creator A5068281424 @default.
• W2959649660 creator A5071466957 @default.
• W2959649660 creator A5077504536 @default.
• W2959649660 creator A5091882595 @default.
• W2959649660 date "2019-05-20" @default.
• W2959649660 modified "2023-10-07" @default.
• W2959649660 title "Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis." @default.
• W2959649660 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.7521" @default.
• W2959649660 hasPublicationYear "2019" @default.
• W2959649660 type Work @default.
• W2959649660 sameAs 2959649660 @default.
• W2959649660 citedByCount "7" @default.
• W2959649660 countsByYear W29596496602019 @default.
• W2959649660 countsByYear W29596496602020 @default.
• W2959649660 countsByYear W29596496602021 @default.
• W2959649660 crossrefType "journal-article" @default.
• W2959649660 hasAuthorship W2959649660A5007316044 @default.
• W2959649660 hasAuthorship W2959649660A5007901103 @default.
• W2959649660 hasAuthorship W2959649660A5013293066 @default.
• W2959649660 hasAuthorship W2959649660A5014125875 @default.
• W2959649660 hasAuthorship W2959649660A5016764336 @default.
• W2959649660 hasAuthorship W2959649660A5024389256 @default.
• W2959649660 hasAuthorship W2959649660A5035549893 @default.
• W2959649660 hasAuthorship W2959649660A5041745367 @default.
• W2959649660 hasAuthorship W2959649660A5046049357 @default.
• W2959649660 hasAuthorship W2959649660A5050782079 @default.
• W2959649660 hasAuthorship W2959649660A5061317839 @default.
• W2959649660 hasAuthorship W2959649660A5063710613 @default.
• W2959649660 hasAuthorship W2959649660A5068281424 @default.
• W2959649660 hasAuthorship W2959649660A5071466957 @default.
• W2959649660 hasAuthorship W2959649660A5077504536 @default.
• W2959649660 hasAuthorship W2959649660A5091882595 @default.
• W2959649660 hasConcept C121332964 @default.
• W2959649660 hasConcept C126322002 @default.
• W2959649660 hasConcept C142424586 @default.
• W2959649660 hasConcept C143998085 @default.
• W2959649660 hasConcept C2776063141 @default.
• W2959649660 hasConcept C2776364478 @default.
• W2959649660 hasConcept C2778559949 @default.
• W2959649660 hasConcept C2779338263 @default.
• W2959649660 hasConcept C2989005 @default.
• W2959649660 hasConcept C31760486 @default.
• W2959649660 hasConcept C535046627 @default.
• W2959649660 hasConcept C71924100 @default.
• W2959649660 hasConcept C87355193 @default.
• W2959649660 hasConceptScore W2959649660C121332964 @default.
• W2959649660 hasConceptScore W2959649660C126322002 @default.
• W2959649660 hasConceptScore W2959649660C142424586 @default.
• W2959649660 hasConceptScore W2959649660C143998085 @default.
• W2959649660 hasConceptScore W2959649660C2776063141 @default.
• W2959649660 hasConceptScore W2959649660C2776364478 @default.
• W2959649660 hasConceptScore W2959649660C2778559949 @default.
• W2959649660 hasConceptScore W2959649660C2779338263 @default.
• W2959649660 hasConceptScore W2959649660C2989005 @default.
• W2959649660 hasConceptScore W2959649660C31760486 @default.
• W2959649660 hasConceptScore W2959649660C535046627 @default.
• W2959649660 hasConceptScore W2959649660C71924100 @default.
• W2959649660 hasConceptScore W2959649660C87355193 @default.
• W2959649660 hasLocation W29596496601 @default.
• W2959649660 hasOpenAccess W2959649660 @default.
• W2959649660 hasPrimaryLocation W29596496601 @default.
• W2959649660 hasRelatedWork W2240926661 @default.
• W2959649660 hasRelatedWork W2241210653 @default.
• W2959649660 hasRelatedWork W2735855342 @default.
• W2959649660 hasRelatedWork W2753212558 @default.
• W2959649660 hasRelatedWork W2785526798 @default.
• W2959649660 hasRelatedWork W2795488556 @default.
• W2959649660 hasRelatedWork W2890277077 @default.
• W2959649660 hasRelatedWork W2899026721 @default.
• W2959649660 hasRelatedWork W2950927135 @default.
• W2959649660 hasRelatedWork W2951168589 @default.
• W2959649660 hasRelatedWork W2952411205 @default.
• W2959649660 hasRelatedWork W2953058729 @default.
• W2959649660 hasRelatedWork W3028800054 @default.
• W2959649660 hasRelatedWork W3032094827 @default.
• W2959649660 hasRelatedWork W3166843757 @default.
• W2959649660 hasRelatedWork W3167968997 @default.
• W2959649660 hasRelatedWork W3172444569 @default.
• W2959649660 hasRelatedWork W3175170408 @default.
• W2959649660 hasRelatedWork W3175700534 @default.
• W2959649660 hasRelatedWork W3177167053 @default.
• W2959649660 isParatext "false" @default.
• W2959649660 isRetracted "false" @default.
• W2959649660 magId "2959649660" @default.
• W2959649660 workType "article" @default.